


AZD4320

Cat. No.:	HY-112416		
CAS No.:	1357576-48-7		
Molecular Formula:	C ₄₅ H ₄₈ ClF ₃ N ₄ O ₇ S ₃		
Molecular Weight:	945.53		
Target:	Bcl-2 Family		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (105.76 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions	1 mM	1.0576 mL	5.2880 mL
		5 mM	1.0576 mL	2.1152 mL
		10 mM	0.1058 mL	0.5288 mL
	Please refer to the solubility information to select the appropriate solvent.			
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (6.61 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC ₅₀ s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.	
IC ₅₀ & Target	BCL2 17 nM (IC ₅₀ , KPUM-UH1 cells)	BCLxL 17 nM (IC ₅₀ , KPUM-UH1 cells)
In Vitro	AZD4320 potently augments the antitumor effect of AZD5153 (Cat. No.: HY-100653A) in double expressing lymphoma (DEL)- and double hit lymphoma (DHL)-derived cell lines in a dose-dependent manner. AZD4320 shows mostly synergistic, and at least additive, growth inhibitory effects on DEL- and DHL derived cell lines, and profoundly increases cells undergoing apoptosis in all three cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

PROTOCOL

Cell Assay ^[1]

Two DEL-derived cell lines, KPUM-MS3 and KPUM-UH1, and a DHL-derived cell line, STR-428 are used. To examine the combinatory growth inhibitory effects of AZD4320, cells are treated with five concentrations (0.25, 0.5, 1.0, 2.0, 4.0×IC₅₀) for 72 h, and subjected to a modified MTT assay^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2023 Sep 19;14(1):5709.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Takimoto-Shimomura T, et al. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs. 2018 Jun 21.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA